Polyethylenimine (PEI)-DNA complexes are nanoparticles that are able to efficiently transfer plasmids to the lungs. Interleukin-12 (IL12) gene transfer using PEI may represent an important strategy for lung cancer treatment. In this study, we evaluated the antitumoral efficacy of the administration of PEI-DNA nanoparticles carrying IL12 gene (PEI-IL12) for the treatment of lung cancer and pulmonary metastases in animal models. After inoculation of tumor cells, mice were treated intravenously with a single dose of PEI-IL12, PEI nanoparticles carrying the reporter gene b-galactosidase (PEI-LacZ) or vehicle. Transgene expression, survival rates and immune response were analyzed in both models. Administration of PEI-LacZ and PEI-IL12 nanoparticles controlled tumor growth and prolonged survival times in both animal models. Although PEI-IL12 and PEI-LacZ administration showed similar antitumoral effects in the lung cancer model, the efficacy of PEI-IL12 was significantly superior in the inhibition of the development of pulmonary metastases. Furthermore, the administration of PEI-DNA nanoparticles results in the production of high levels of proinflammatory cytokines. Our results showed that PEI-DNA nanoparticles are an efficient vector for mediating gene transfer to the lungs, are a potent inducer of the innate immune response and represents an interesting strategy for the treatment of bronchogenic carcinoma and metastatic lung carcinoma.
Introduction
Bronchogenic carcinoma is presently the most common malignant disease worldwide, representing 12.3% of all the malignant tumors, accounting for an estimated 162 460 deaths in 2006, in the United States. 1, 2 In spite of the introduction of multimodal treatments and despite the advances in chemotherapy, radiation therapy and surgery, the overall survival is o15%. 3 Owing to its high frequency and its bad prognosis, it is an interesting field for the development of new modalities of treatment that replaces or complements the present ones. Interleukin-12 (IL12) is a cytokine produced by antigen-presenting cells, which is essential in the induction of effective cellmediated immunity against cancer and infectious disease. 4 IL12 exerts its antitumor activity preventing the growth of tumors, causing regressions of established tumors and diminishing its spontaneous appearance in mice with predisposition or exposed to carcinogenic substances. [5] [6] [7] The promising results obtained in tumor animal models led to several clinical trials. 8, 9 Gene therapy is able to significantly increase therapeutic protein expression in the tumor without excessive elevation of systemic levels, leading to an increased efficacy/toxicity ratio. Gene delivery of immunostimulatory cytokines, such as IL12 or IFN-b, has been shown to be highly effective in eradicating tumors in different animal models including lung cancer. [10] [11] [12] [13] More importantly, clinical trials in nonsmall-cell lung cancer immunogene therapy have shown promise with the induction of immune responses and the presence of clinical responses. 14, 15 Gene therapy needs not only a therapeutic genetic material to transfer, but also a vector to transport the therapeutic gene to the target tissue. Gene-therapy vectors can be divided into viral and non-viral vectors. Among non-viral vectors, polyethylenimine (PEI) is considered as one of the most effective vectors. PEI is a cationic polymer able to compact the DNA by electrostatic interaction between the imine groups of PEI and the phosphate groups of DNA. 16 Its effectiveness as vector to transfer genetic material has been shown in a number of works both in vitro and in vivo. [17] [18] [19] [20] Preclinical data are available for several cancer models including lung cancer. 20 Currently, PEI-DNA are being used in phase II for the treatment of bladder cancer, and phase I studies has shown a good safety profile. 21 In vivo, systemic-delivered PEI-DNA complexes resulted in the transduction of the lung. 22 Thus, the intravenous administration of PEI-DNA complexes is an attractive method to deliver DNA into the lung.
We hypothesized that local pulmonary gene transfer of IL12 would protect the lungs from the development of cancer. Thus, we examine the antitumoral efficacy of the systemic administration of PEI-DNA nanoparticles carrying a plasmid codifying for IL12 in a murine model of lung cancer and in a model of pulmonary metastasis.
Materials and methods

Animals and cells
C57BL/6J and BALB/c female mice, 5-6 weeks old, were obtained from Harlan Laboratories (Barcelona, Spain) and maintained according to the regulations of our institution. LLC cells were obtained from the ATCC (CRL-1642). Murine CT26 cells have originally been described by Brattain et al. 23 To analyze the immune response by ELISPOT assay, two different cell lines were used: MC38 and P815. 24 Cells were cultured and maintained in complete DMEM medium.
Bioluminescence measurement in living mice
Mice were anaesthetized using ketamine/xilacine and 100 ml of D-luciferine (Xenogen, Alameda, CA) at a concentration of 30 mg ml -1 were injected by intraperitoneal route. Luciferase expression was analyzed using a Xenogen IVIS system (Xenogen Corp., Alameda, CA), as described earlier. 25 Murine tumor models and treatment Lung cancer was induced by tail vein injection of 5 Â 10 5 LLC cells in C57BL/6J mice and pulmonary metastases were induced by tail vein injection of 1 Â 10 6 CT26 cells in BALB/c mice. PEI-DNA complexes were injected intravenously one or four days after tumor cell injection, as a single 400 ml volume through tail vein. Experiments involving animals were conducted according to the institutional guidelines for animal care. Mice were killed whenever the sanitary status of the animals commanded, so as to avoid unnecessary suffering.
Plasmid DNA and CpG sequence analysis Plasmids containing the IL12, b-galactosidase and luciferase genes under the control of the human cytomegalovirus promoter were produced and purified according to the manufacturer's protocol (Quiagen, Valencia, CA) and then dissolved in endotoxin-free 5% glucose solution (GS) to the desired concentration. To analyze the CpG content in the plasmids, CpG dinucleotides were found when searching both strands and were divided by the number of base pairs. The 'fuzznuc' algorithm (EMBOSS program; http://mobyle.pasteur.fr/cgi-bin/MobylePortal/portal.py? form ¼ fuzznuc) was used for the searches. 26 The analysis revealed that the CpG content of the b-galactosidase and IL12-expressing plasmids were similar (7.4% and 4.5%, respectively).
Preparation of PEI-DNA nanoparticles
In vivo-jet PEI was from Polyplus-transfection (Illkirch, France). The desired amount of DNA in GS was complexed with PEI 22 kDa by adding the PEI to the DNA, while vigorously vortexing the solution. PEI-DNA complexes were formed at a molar ratio of PEI nitrogen to DNA phosphate of 4 (N/P ¼ 4). The size and zeta potential of the PEI-DNA nanoparticles were measured by photon correlation spectroscopy and laser Doppler anemometry, respectively, using a Zetamaster Analyzer system (Malvern Instruments, Southborough). Size measurements were performed at 25 1C and a 901 scattering angle, and was recorded for 90 s for each measurement. The mean hydrodynamic diameter was generated by cumulative analysis. The zeta potential measurements were performed with an aqueous dip cell in the automatic mode. Moreover, the shape and size of the PEI-DNA particles were examined by scanning electron microscopy in a Zeiss DSM-940A digital scanning electron microscope (Oberkochen, Germany). Particle analysis data showed that we could reproducibly prepare DNAcontaining PEI nanoparticles with an average particle size of 200 nm and a charge of 50 mV.
Cytokine assays
Plasma samples were clarified and stored at À20 1C. IL12 and IFN-g concentrations were determined by a sandwich enzyme-linked immunosorbent assay (Pharmingen, San Diego CA) according to the manufacturer's protocol.
Quantification of tumor-specific CD8
þ T cells by ELISPOT assay We determined the number of CD8 þ T cells that recognized tumor antigens in PEI-DNA-treated mice by isolating splenocytes and stimulating them with the tumor cell line or in the case of CT26 with P815 cells loaded with the AH1 peptide (RIQRGPGRAFVTIGK). ELISPOT assay to determine the number of IFN-g-producing cells was performed as described earlier. 24 The background level, namely the number of cells that secrete IFN-g in the absence of antigen, was subtracted in every experimental group.
Statistical analysis
The comparison of quantitative variables was made with the aid of the program Instat (GraphPad Inc. Software). Data presented as percentage of tumor-free animals were analyzed with Kaplan-Meier survival curves, using the log-rank test to determine statistical significance. ELI-SPOT results were compared using ANOVA followed by a Student-Newman-Keuls test, performed using SPSS (SPSS, Inc., Chicago, IL). Differences were deemed significant for a real a of 0.05.
Results
In vitro and in vivo transfection studies First, we wanted to verify whether PEI-DNA nanoparticles were able to transduce the tumor cell lines LLC and CT26, and the lungs of BALB/c mice. For in vitro studies, 5 Â 10 4 LLC and CT26 cells in culture were transfected with PEI-LacZ using 3 mg of DNA, respectively. The complexes were formed in saline solution and using an N/P ratio of 4. The expression of b-galactosidase in the cells was analyzed 24 h after transfection by staining with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal). As shown in Figure 1a , the percentage of transfected cells was around 5% for LLC cells and around 10% for CT26 cells. Next, we analyzed in vivo the transduction efficiency of the lungs by PEI-DNA complexes using a plasmidexpressing luciferase (PEI-Luc). PEI-Luc and PEI-LacZ complexes were prepared at N/P ratio of 4 and carried 100 mg of plasmid. Two groups of five mice were injected through tail vein in a total volume of 400 ml with either PEI-Lacz or PEI-Luc; 6 h after nanoparticle injection, luciferase expression was analyzed in all the animals. As shown in Figure 1b , luciferase expression was localized in the lungs of the mice that have received PEI-Luc, but not in the mice receiving the b-galactosidase-expressing plasmid. Two of the mice were killed and the luciferase expression was tested in lung extracts and in other organs to corroborate in vivo results (data not shown).
Antitumoral efficacy of PEI-DNA complexes in murine lung cancer model C57BL/6 mice were inoculated with 5 Â 10 5 LLC tumor cells through tail vein; 24 h later, mice were divided into 3 groups, a group of 15 mice were treated intravenously with PEI-LacZ complexes, a group of 15 mice were treated with PEI-IL12 complexes and a group of 7 mice received an equivalent volume of GS as control. The PEI-DNA complexes were prepared at N/P ratio of 4 and carried 100 mg of plasmid. As shown in Figure 2 , independently of the transgene, the treatment with PEI-DNA complexes showed a significant antitumor effect when compared with vehicle-treated group. None of the animals treated with GS survived (0/7), whereas in the group of mice treated with PEI-IL12 or PEI-LacZ, the survival rate was 53% (8/15) and 60% (9/15), respectively. There were no significant differences on the survival rate between PEI-LacZ and PEI-IL12-treated groups. Ninety-two days after tumor cell injection, the surviving mice and a group of naı¨ve control mice were injected intravenously with 5 Â 10 5 LLC cells. After re-challenge, all the mice died and no differences in survival times were found among groups (Figure 2 ). LLC and CT26 were transfected with PEI-DNA complexes carrying a 2 and 3 mg, respectively, of plasmid DNA encoding for b-galactosidase (pCMV-LacZ). After staining, positive cells were observed for both cell lines (a). BALB/c mice were injected through tail vein with 100 mg of PEI-LacZ or PEI-Luc complexes at an N/P 4 in 400 ml of 5% glucose; 6 h later, luciferase expression was analyzed using a CCD camera. A positive signal was detected in lung of PEI-Luctreated mice (b).
Figure 2
Effect of PEI-DNA immunotherapy in a lung cancer model; 5 Â 10 5 LLC cells were injected intravenously into C57BL/6 mice. One day later, they were divided into three different groups and treated with 5% GS (5%) (circles, n ¼ 7), PEI-LacZ (triangles, n ¼ 15) and PEI-IL12 (squares, n ¼ 15). The complexes were formed with 100 mg of plasmid and at N/P ratio of 4. The survival of the three groups was analyzed. Kaplan-Meier survival plot shows the effect of intravenous injection of PEI-IL12 and PEI-LacZ in the treatment of lung cancer and survival was compared by log-rank test. ***Po0.001. No differences were observed between PEI-LacZ and PEI-IL12. There were no further changes in survival for up to 3 months in the treated mice. At this time point, the animals received a second dose of LLC cells. Kaplan-Meier survival plot shows no difference among groups.
Antitumoral efficacy of PEI-DNA complexes in murine pulmonary metastasis of colon cancer In the model of pulmonary metastasis of colon cancer, BALB/c mice received 1 Â 10 6 CT26 cells through tail vein. One day later, mice were divided into three different groups (n ¼ 10) and treated with GS, PEI-LacZ and PEI-IL12. The PEI-DNA complexes were formed as described earlier using 100 mg of plasmid. All the mice from GS group died before day 30. In the group that received treatment with PEI-LacZ, 50% of them survived (5/10), whereas all the mice survived in the group that received PEI-IL12 (10/10). The differences on the survival rate between GS group, and PEI-LacZ and PEI-IL12 groups were statistically significant (Po0.05), as well as between PEI-LacZ and PEI-IL12 (Figure 3 ). All the mice that survived to tumor injection received a second injection of 1 Â 10 6 CT26 at day 109. All of the animals except one survived to re-challenge ( Figure 3 ).
Antitumoral efficacy of PEI-DNA complexes in a murine model of established pulmonary metastasis of colon cancer In this model, BALB/c mice received 1 Â 10 6 CT26 cells through tail vein and the treatment was given 4 days later. Mice were divided into three different groups (n ¼ 10) and were treated with GS, PEI-LacZ, and PEI-IL12 nanoparticles. As shown in Figure 4 , none of the mice from the control groups, GS or PEI-LacZ, survived. In contrast, 20% of the mice that received PEI-IL12 complexes survived and were protected after re-challenge that was performed 103 days after the first injection, for up to a year. Furthermore, it is noteworthy to say that the number of pulmonary metastasis found in the animals treated with GS or PEI-LacZ was higher than in the group treated with PEI-IL12 (data not shown).
Analysis of cytokine expression IL12 and IFN-g expression was analyzed in the serum of mice that received PEI-IL12, PEI-LacZ or GS. The PEI-DNA complexes were prepared at N/P ratio of 4 and carried 100 mg of plasmid. Six mice per group were injected and the cytokine concentration in serum was analyzed after 6, 12 h, 1, 2, 3 and 5 days. We also analyzed cytokine expression in mice treated with 100 mg of naked DNA or 12 ml of PEI 100 mM administered through tail vein. No IL12 was detected in the mice that received GS, naked DNA or PEI (Supplementary Figure 1) , whereas the levels of both cytokines were elevated in the serum of the group of mice treated with PEI-DNA complexes, independently of the plasmid they carried (LacZ or IL12) (Figure 5a ). The maximum level of protein expression in both the groups was reached 6 h after the injection of PEI-DNA complex and maintained during the first 24 h. At day 2, significant differences were found between the two groups, as IL12 was detected only in two out of six mice from PEI-LacZ group, whereas in PEI-IL12 group five out of six mice express IL12 out to day 5. This difference in the duration of IL12 expression may be the reason for the higher antitumoral efficacy found in the PEI-IL12 group in the CT26 models (Figures 3 and 4) . IFN-g expression analysis showed no significant differences between the groups that received the PEI-DNA complexes, and the higher level of protein expression was detected 6 h after the injection of the complexes (Figure 5b) .
Analysis of the antitumoral immune response CD8
þ T-cell-specific immune response has been shown to have an essential function in tumor rejection. Thus, we Figure 3 Effect of PEI-DNA immunotherapy in a model of recent pulmonary metastasis of colon cancer; 1 Â 10 6 CT26 cells were injected intravenously into BALB/c mice. One day later, they were divided into three different groups and treated with 5% GS (5%) (circles, n ¼ 10), PEI-LacZ (triangles, n ¼ 10) and PEI-IL12 (squares, n ¼ 10). The complexes were formed with 100 mg of plasmid and at N/P ratio of 4. The survival of the three groups was analyzed. Kaplan-Meier survival plot shows the effect of intravenous injection of PEI-IL12 and PEI-LacZ in the treatment of recent pulmonary metastasis and survival was compared by log-rank test. ***Po0.001. There were no further changes in survival for up to 4 months in the treated mice. At this time point, the animals received a second dose of CT26 cells. All the survival animals were protected. Figure 4 Effect of PEI-DNA immunotherapy in a model of established pulmonary metastasis of colon cancer; 1 Â 10 6 CT26 cells were injected intravenously into BALB/c mice. Four days later, they were divided into three different groups and treated with 5% GS (5%) (circles, n ¼ 7), PEI-LacZ (triangles, n ¼ 11) and PEI-IL12 (squares, n ¼ 10). The complexes were formed with 100 mg of plasmid and at N/P ratio of 4. The survival of the three groups was analyzed. Kaplan-Meier survival plot shows the effect of intravenous injection of PEI-IL12 in the treatment of established pulmonary metastasis and survival was compared by log-rank test. *Po0.05. No differences were found between PEI-LacZ and GS 5%. There were no further changes in survival for up to 4 months. At this time point, the animals received a second dose of CT26 cells. All the survival animals were protected. Nanoparticles in lung cancer treatment M Rodrigo-Garzón et al have analyzed tumor-specific cellular immune response developed in mice that inhibit the development of tumors after treatment with PEI-DNA complexes. The analysis of the cellular immune responses was performed by ELISPOT assay. Mice (n ¼ 5) were injected intravenously with 5 Â 10 5 LLC cells or 1 Â 10 6 CT26, one day later they received GS, PEI-LacZ or PEI-IL12, prepared as described earlier. Fourteen days later, mice were killed and splenocytes were isolated to analyse tumor-specific immune response. Splenocytes from groups of mice that received LLC cell line were stimulated with LLC cells or the syngenic colon cancer MC38 tumor cell line as control. Splenocytes from groups of mice that received CT26 cell line were stimulated with CT26 and P815 pulsed with the CD8-specific CT26 epitope, AH1 or unpulsed P815 as control. The analysis was made separately with each animal and the results shown in Figure 6 correspond to the average of the values obtained from each mouse. The analysis of the immune response in lung cancer model revealed no significant differences in the number of IFN-g-producing cells between the splenocytes stimulated with LLC or the MC38 control cell line, although a slightly higher number of IFN-gproducing cells were detected in the groups receiving PEI-DNA when they were incubated with LLC cell line. Thus, no specific immune response against LLC was developed in those mice independently of the treatment (Figure 6a ). This result corroborates the absence of protection against re-challenge.
In the model of pulmonary metastasis of colon cancer, splenocytes from the group of mice treated with PEI-DNA complexes and stimulated with CT26 or P815 cells pulsed with AH1 showed an important specific immune response in comparison to splenocytes stimulated with unpulsed P815 cells. Significant differences in the magnitude of the immune response were found between the group of mice that received GS and the groups treated with PEI-DNA complexes; however, no significant differences in the immune response were found between PEI-LacZ-and PEI-IL12-treated groups (Figure 6b ). Figure 6 Tumor-specific cellular immune response. Groups of five C57BL/6 mice were injected intravenously with 5 Â 10 5 LLC cells, one day later they received GS 5%, PEI-LacZ (100 mg) or PEI-IL12 (100 mg). Fourteen days later, mice were killed and splenocytes from these animals were isolated. After incubation for 24 h with LLC or MC38 cell lines, the mean number of IFN-g-producing spot-forming cells (SFC) in ELISPOT wells was enumerated with an automated spot-counting system and mean number of SFC per 1 Â 10 6 splenocytes is shown (a). Groups of five BALB/c mice were injected intravenously with 1 Â 10 6 CT26 cells, one day later they received GS 5%, PEI-LacZ (100 mg) or PEI-IL12 (100 mg). Fourteen days later, mice were killed and splenocytes from these animals were isolated. After incubation for 24 h with CT26, AH-1 pulsed P815 cells and nonpulsed P815 cells mean number of IFN-g-producing SFC in ELISPOT wells was enumerated with an automated spot-counting system and mean number of SFC per 1 Â 10 6 splenocytes is shown. **Po0.01 (b).
Discussion
This study showed that the intravenous administration of PEI-DNA nanoparticles, apart from being able to transferring genetic material to the lung, induces a strong innate immune response that inhibits lung cancer and pulmonary metastases development. This antitumoral effect was further increased with the expression of cytokines with immunostimulatory activities. IL12 is a cytokine with a strong antitumoral activity, mainly mediated by the induction of IFN-g. 4 IL12 exerts its antitumoral activity through the activation of the innate and acquired immune system: increases the cytotoxic activity of NK and NKT, promotes the formation of tumor-specific cytotoxic T lymphocytes and, in addition, inhibits tumor angiogenesis. [5] [6] [7] 13, 27 Furthermore, other cells such as dendritic cells, endothelial cells, macrophages, neutrophils, which are implicated in the development of antitumor immune responses, are activated by IL12. 4, 27 Our results showed that intravenous administration of PEI-IL12 nanoparticles resulted in elevated serum levels of IL12 and this expression is able to stimulate an immune response that inhibits the development of tumors. However, to our surprise, an important antitumoral efficacy was obtained in the group of mice that received the PEI-DNA complexes expressing the reporter gene b-galactosidase.
The analysis of cytokine expression shed light on reasons for the strong antitumoral efficacy shown in the group of mice treated with PEI-DNA carrying the control plasmid-expressing b-galactosidase. Similar levels of IL12 and IFN-g were reached in the serum of the mice receiving PEI-DNA nanoparticles independently of the transgene they expressed. However, differences were found regarding the duration of IL12 expression, which was longer in the mice receiving PEI-IL12 nanoparticles. Our explanation for the high levels of cytokines detected after nanoparticle injection is that some of the cells (macrophages or dendritric cells) transduced by PEI-DNA complexes get activated by the non-methylated CpG sequence present in both plasmids and produce elevated amounts of IL12 (Figure 5a ). These sequences are frequently found in DNA of bacterial origin and are recognized as pathogen-associated molecular patterns by the immune system of the mammals leading to the activation of the innate immune system. [28] [29] [30] Once activated, monocytes, macrophages and/or dendritic cells produce large amounts of IL12, 31, 32 which in turn induce IFN-g secretion by NK and NKT cells and enhance their cytolitic activity. 30, 33 This activation affects not only the innate immune system, but also the development of CD8 þ and CD4 þ T cells, which will be biased to a Th1 pattern. 34, 35 This phenomenon could be detrimental if toxic levels of cytokines are reached, or if we want to obtain a long-term transgene expression, as the immune response attenuates the promoter and could even completely abrogate its activity (silencing). 36, 37 Nevertheless in other situations, such as vaccinations or antitumor treatments, this stimulation of the immune system is beneficial and might act synergistically with the antitumoral transgene used in the treatment. [38] [39] [40] [41] This activation at first is non-specific and is independent of the transgene, but in the presence of a foreign antigen, in this case tumor antigens, the expression of these immunostimulatory cytokines is able to induce a strong immune response against the tumor cells. The isolated administration of plasmid IL12 or the vector does not produce any effect, as the entrance of the CpG in macrophages and/or dendritic cells is required to stimulate the production of cytokines, and this is only obtained after the administration of PEI-DNA complexes. 42 As shown in this study, the antitumoral effect observed in mice treated with PEI-DNA complexes is independent of the gene carried by the plasmid suggesting that the administration of a plasmid with no transgene expression and high CpG content will have a similar effect.
Interestingly, differences on the response to the treatment were found depending on the animal model. In lung cancer model, in which we injected LLC cells intravenously, the survival was similar between PEI-LacZ (60%) and PEI-IL12 (53%), and immunological memory was not generated, as all the animals that survived the first injection died on re-challenge. However, in the model of pulmonary metastasis with CT26, the survival rate was clearly higher in the group of mice treated with PEI-IL12 (100%) than in the group of mice treated with PEI-LacZ (50%). In addition, in this model, immunological memory was generated, as the animals that survived rejected a second tumor cell injection. Furthermore, when the pulmonary metastases were treated once they are established in the lung, that is four days after tumor cells injection, only the administration of PEI-DNA complexes expressing IL12 protects against tumor development.
The immune response that was generated in the model of lung cancer induced after LLC intravenous injection was non-specific, as we were not able to detect a specific immune response by ELISPOT analysis and more important, the animals that survived after the treatment were not protected on re-challenge. Nevertheless, in the model of pulmonary metastasis of colon cancer developed after intravenously injection of CT26 cells, specific cytotoxic T lymphocytes and an immunological memory were generated. Significant differences in the number of IFN-g-producing cells were found between the groups treated with PEI-DNA nanoparticles and the untreated group. Furthermore, most of the animals rejected a second injection of tumor cells. Thus, the characteristics of the immune response developed after PEI-DNA injection clearly differs between both models.
The immune system can act against tumors through the activation of the innate and/or acquired immune system, for this reason the development of an antigen-specific immune response is not always a requirement to stop the development of a tumor or to eliminate it. The induction of one or the other type of antitumoral immune response after PEI-DNA treatment will depend on diverse factors such as the immunogenity of the tumor, the levels of serum IL12, the immunological status of the guest and the route of administration. 42 In our case, the main differences between both models are the tumor cell line and the strain of mice. LLC is a poorly immunogenic tumor cell line, whereas CT26 is highly immunogenic. 43 The differences in immunogenicity would explain the differences in the induction of a specific immune response as shown in Figure 6 . Nevertheless, the possibility that the strain of the mice has an important function on the antitumoral response after PEI-DNA administration cannot be excluded. More experiments should be perform using tumor cell lines of different immunogenicity that can be implanted in the same strain of mice to clarify this issue.
In the lung cancer model, no differences were detected between the group receiving LacZ or the group receiving IL12. However, significant differences were observed between both groups of treatment in the recent and established pulmonary metastasis models induced after CT26 injection (Figures 3 and 4) . In both cases, the survival was clearly superior in the group treated with PEI-IL12 than in the group treated with PEI-LacZ, in spite of detecting similar cytokines levels in serum and similar specific immune response ( Figures 5 and 6b) . The difference between both the groups was the presence of longer-lasting levels of IL12 in serum in a greater number of animals in the PEI-IL12 group. These differences must be due to the expression of the transgene in the lung (Figure 1b) and would explain the higher antitumoral activity found in this group. The longer expression of IL12 will induce a more effective cellular immune response in this group. Although no differences were detected in the levels of IFN-g-induced expression during the first 5 days, it is possible that the differences will appear at later time points. Furthermore, IL12 induce the expression of other molecules that have antitumoral activity and we are not analyzing that in this study, which can explain the differences found in the antitumoral effect between the two treatments.
In summary, our data show that intravenous administration of PEI-DNA nanoparticles is an efficient way to transfer genetic material to the lungs. However, its antitumoral efficacy not only resides in the transgene they carry, but also on the activation of the innate immune response by the CpG-containing motifs. In the case of lung cancer model, the antitumoral activity is mainly because of the activation of the innate immune system by the CpG motifs, but in CT26 model, the antitumoral activity of local recombinant IL12 expression has a significant function. As bronchogenic carcinoma is frequently high and very difficult to treat, alternative approaches are warranted. Among them, gene therapy based on the administration of PEI-DNA complexes might offer a novel therapeutic approach for bronchogenic carcinoma. Our data support the necessity of more studies to value their future application in the treatment of the bronchogenic carcinoma and other fields, such as genetic vaccines.
